

Brilliant Violet 785™ anti-human CD335 (NKp46)

Catalog # / 2259730 / 100 tests
Size: 2259725 / 25 tests

Clone: 9E2

Isotype: Mouse IgG1, κ


Immunogen: NKp46-Fc fusion protein

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 785™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD56 PE and CD335 (NKp46) (clone 9E2) Brilliant Violet 785™ (left) or Mouse IgG1, κ Brilliant Violet 785™ isotype control (right)

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Clone 9E2 has been shown to block NK activation through NKp46.⁶

- Application References:**
1. Nakajima H, *et al.* 2000. *Eur. J. Immunol.* 30:3309.
 2. Kalberer CP, *et al.* 2003. *Blood* 102:127.
 3. Chen Y, *et al.* 2007. *J. Immunol.* 179:2766.
 4. Jarahian M, *et al.* 2009. *J. Virol.* 83:8108. [PubMed](#)
 5. Correia DV, *et al.* 2011. *Blood* 118:992. (FC) [PubMed](#)
 6. Achdout H. *et al.* 2010. *J. Virol.* 84:3993.

Description: CD335, also known as NKp46, is a member of the natural cytotoxicity receptor (NCR) family which triggers cytotoxicity in NK cells. CD335 is directly involved in target cell recognition and lysis, and is exclusively expressed on CD3⁻CD56⁺ NK cells, suggesting it is a universal marker for NK cells. NKp46, along with NKp30 and NKp44, is referred to as a natural cytotoxicity receptor (NCR) and plays a very important role in killing virus-infected tumor cells and MHC-class I-unprotected cells.

Antigen
References:

1. Mandelboim O and Porgador A. 2001. *Int. J. Biochem. Cell Biol.* 33:1147.
2. Nakajima H, et al. 2000. *Eur. J. Immunol.* 30:3309.
3. Sivori S. 1999. *Eur. J. Immunol.* 29:1656.